HR 6227 United States House · 118th Congress

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Summary

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Issues: ✓ Healthcare

Bill status in committee 1 of 4 stages cleared

Introduction

Nov 2023

Committee Review

Floor Vote

President

Introduced Nov 3, 2023 Last action Nov 10, 2023

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

3

Key actions

0

Committee

2

Nov 10, 2023

Committee

Referred to the Subcommittee on Health.

lower

Nov 3, 2023

Committee

Referred to the House Committee on Energy and Commerce.

lower

Nov 3, 2023

Introduced

Introduced in House

lower

1 primary · 35 co-sponsors

Sponsors

Role

Legislator

Party

State

District

David Schweikert

Brittany Pettersen

David G. Valadao

Diana Harshbarger